|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Keytruda
|
|
gptkbp:advocates_for
|
required for participation
|
|
gptkbp:affiliated_with
|
gptkb:XYZ_University
|
|
gptkbp:analysis
|
statistical methods applied
|
|
gptkbp:analyzes
|
gptkb:Dr._Jane_Smith
gptkb:Dr._John_Doe
|
|
gptkbp:business_model
|
obtained from relevant boards
|
|
gptkbp:clinical_trial
|
gptkb:III
NC T03307775
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
|
|
gptkbp:collection
|
ongoing
|
|
gptkbp:country
|
gptkb:government_agency
gptkb:Australia
gptkb:Japan
gptkb:Monarch
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:criteria
|
previous treatment with anti-PD-1 therapy
adult patients with NSCLC
|
|
gptkbp:current_use
|
gptkb:healthcare_organization
|
|
gptkbp:duration
|
24 months
|
|
gptkbp:finale_date
|
quality of life assessment
overall survival rate
|
|
gptkbp:honorific_prefix
|
NC T03307775
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
KEYNOTE-598
|
|
gptkbp:is_compared_to
|
Pembrolizumab vs chemotherapy
|
|
gptkbp:is_monitored_by
|
conducted by independent committee
|
|
gptkbp:is_protected_by
|
gptkb:Pembrolizumab
|
|
gptkbp:is_studied_in
|
randomized, open-label
|
|
gptkbp:is_tested_for
|
Phase 3
|
|
gptkbp:launch_date
|
2017-06-01
|
|
gptkbp:location
|
multiple locations
|
|
gptkbp:participants
|
overall survival
progression-free survival
|
|
gptkbp:pharmacokinetics
|
gptkb:Pembrolizumab
chemotherapy
|
|
gptkbp:population
|
diverse population
|
|
gptkbp:primary_source
|
treatment
|
|
gptkbp:provides_information_on
|
available upon request
standard of care
|
|
gptkbp:publishes
|
results expected in 2024
|
|
gptkbp:recorded_by
|
1:1 ratio
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:research
|
pending
interventional
Pembrolizumab improves survival
|
|
gptkbp:research_focus
|
immunotherapy in lung cancer
|
|
gptkbp:result
|
not yet published
|
|
gptkbp:safety_features
|
performed regularly
|
|
gptkbp:side_effect
|
monitored throughout the study
|
|
gptkbp:sponsor
|
gptkb:Merck_&_Co.
|
|
gptkbp:status
|
active, not recruiting
|
|
gptkbp:student_enrollment
|
approximately 600 participants
|
|
gptkbp:treatment
|
two
|
|
gptkbp:vision
|
open label
|
|
gptkbp:year
|
2023-12-31
|